Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Centessa Initiates Phase 2 Trial with ORX750, Resulting in US$3.5 Million Milestone Payment to Nxera Pharma
Nov 13, 2024
Contract Type
partnership
TokyoBiotechnologyPharmaceutical
Description
Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, resulting in a milestone payment of US$3.5 million to Nxera Pharma. The milestone payment is part of Nxera's research collaboration with Centessa for the development of ORX750, an orexin receptor 2 (OX2R) agonist for the treatment of sleep/wake disorders.
Company Information
Company
Nxera Pharma Ltd
Location
Tokyo, Tokyo, Japan
About
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates.
TokyoBiotechnologyPharmaceutical